A partnership between CEPI, Barinthus Biotherapeutics and the University of Oxford aims to fast-track the development of a potential vaccine for the prevention of Middle East Respiratory Syndrome (MERS).
Using data from 7 million people notified by the NHS COVID-19 contact tracing app, this is the first large-scale study to reveal how duration and proximity of contact with an infected person affects how COVID-19 is spread.
New University of Oxford research brings to light important ethical considerations in Nipah virus outbreak control, its treatment, and research into vaccines.
PSI has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.
Scientific advisors to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford\u2019s vaccine laboratories as part of a two-day meeting of the global coalition.
CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Jun\u00edn virus, with a new project led by Professor Teresa Lambe.
The RECOVERY trial, the leading global clinical trial of treatments for COVID-19, has expanded to find effective treatments for patients hospitalised with flu.
Research published today brings together for the first time the epidemiology and evolution of the SARS-CoV-2 virus in the UK during the first three years of the pandemic \u2013 including how variants emerged and spread.
Clinical researchers and representatives from the World Health Organization defined a bold new path for global research collaboration in acute care at a conference co-hosted by ISARIC, a global federation of investigator-led clinical research networks.
The University of Oxford has launched a new global vaccine collaboration, backed by \u00a38 million funding from UK Research and Innovation (UKRI), and led by two PSI Principal Investigators.
Professor Dame Sarah Gilbert, the Oxford Project Leader for the Oxford-AstraZeneca COVID-19 vaccine and Pandemic Sciences Institute researcher, has received the Freedom of the City of London in recognition of her outstanding achievements in, and contribution to, science and public health.
The UK trial is the next step in the development of a vaccine to protect people against MERS \u2013 a deadly viral illness with no current vaccines and the potential to cause a pandemic.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
PSI Director Professor Sir Peter Horby explains how relationships across scientific disciplines, sectors and global regions are key to preventing and preparing for future pandemics.
Representatives from academia, industry, policy and civil society are gathering in Oxford next week to discuss the latest scientific advances that are ensuring the world is better prepared for future pandemics.
![\"Healthworker](\"https://www.psi.ox.ac.uk/news-and-opinion/new-partnership-aims-to-advance-vaccine-against-mers-coronavirus/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n